KRAS, NRAS, hras-mutated NSCLC

Clinical trials for KRAS, NRAS, hras-mutated NSCLC explained in plain language.

Never miss a new study

Get alerted when new KRAS, NRAS, hras-mutated NSCLC trials appear

Sign up with your email to follow new studies for KRAS, NRAS, hras-mutated NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for Hard-to-Treat lung cancer: targeted drug combo trial launches

Disease control Recruiting now

This study is testing new drugs called RAS(ON) inhibitors for people with advanced non-small cell lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors or slow the cancer's growth. About 616 adults who have already tried standard tr…

Matched conditions: KRAS, NRAS, HRAS-MUTATED NSCLC

Phase 1/2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control

Last updated Jul 02, 2026 00:00 UTC

KRAS, NRAS, hras-mutated NSCLC

Get alerted when new KRAS, NRAS, hras-mutated NSCLC trials appear

New hope for Hard-to-Treat lung cancer: targeted drug combo trial launches